February 7,
2007
By
Laurie Brunette and Asher Kimchi M.D.
San Francisco,
CA -
Statins are known to reduce the rate of major cardiovascular
events through their lipid lowering effects, but their potential
benefit as treatment for HF is largely unexplored. Kiran K.
Khush et al from
University of
California,
San Francisco School of Medicine compared the effects of two
doses of the same statin formulation to determine their impact
on the incidence of hospitalization for HF among the two
treatment arms. This study, which was published in the February
6, 2007 issue of Circulation, found that intensive
treatment with atorvastatin in patients with stable coronary
artery disease significantly reduced subsequent hospitalizations
for HF compared with low-dose therapy. This benefit was most
pronounced in patients with a history of HF.
This study of
10,001 patients included men and women 35 to 75 years old with
clinically evident coronary heart disease (CHD), defined as previous myocardial infarction (MI),
prior or current angina with objective evidence of
CHD, or a
history of coronary revascularization. A history of HF was
present in 7.8% of patients. At the start of the study, patients
discontinued use of any lipid-lowering drugs. Patients entered
the trial if their LDL cholesterol was <130 mg/dL after an
8-week run-in trial on 10 mg/d atorvastatin. These patients were
randomly assigned to double-blind therapy with either 10-mg
(low-dose) or 80-mg (high-dose) atorvastatin daily. The median
follow-up period was 4.9 years. A primary efficacy outcome was
the occurrence of a major cardiovascular event, defined as
nonfatal, non-procedure related MI, resuscitated cardiac arrest,
stroke, or
CHD death. A secondary efficacy outcome was defined as hospitalization for
a primary diagnosis of HF.
The incidence
of hospitalization for HF was 2.4% in the 80-mg arm and 3.3% in
the 10-mg arm (hazard ratio, 0.74; 95% confidence interval, 0.59
to 0.94; P=0.0116). In patients with a previous history of HF,
the benefits of the higher dose were much more pronounced. Among
these patients, the incidence of hospitalization for HF was
10.6% in the 80-mg arm and 17.3% in the 10-mg arm (hazard ratio,
0.59; 95% confidence interval, 0.4 to 0.88; P=0.009). Among
patients without a history of HF, the rates of hospitalization
for HF were much lower: 1.8% in the 80-mg group versus 2.0% in
the 10-mg group (hazard ratio, 0.87; 95% confidence interval,
0.64 to 1.16; P=0.34). Thus, the absolute risk reduction in
hospitalization for HF for the high-dose group was much greater
in patients with a history of HF than without. For each 1 mg/dL
reduction in LDL cholesterol, the risk of hospitalization for HF
decreased by 0.6% (P=0.007). Of those patients with antecedent
myocardial ischemia or MI, only 15.7% experienced their MI or
angina in the 3 months preceding HF hospitalization. A
significant difference between the blood pressure responses
between the 2 treatment groups was not detected.
This study
concludes that high-dose compared with low-dose atorvastatin
significantly reduced the incidence of hospitalization for HF in
patients with stable CHD. This benefit was most pronounced in
patients with a history of HF and is unlikely due primarily to a
reduction in interim coronary events or differences in blood
pressure. The mechanism behind this dose-related effect remains
unknown, but may be do to other factors besides the
lipid-lowering effects of the statin therapy.
Co-authors:
David D. Waters, MD; Vera Bittner, MD; Prakash C. Deedwania, MD;
John J.P. Kastelein, MD; Sandra J. Lewis, MD; Nanette K. Wegner,
MD |